Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Cash & Equivalents (2016 - 2026)

Gyre Therapeutics has reported Cash & Equivalents over the past 16 years, most recently at $37.1 million for Q4 2025.

  • Quarterly Cash & Equivalents rose 214.15% to $37.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $37.1 million through Dec 2025, up 214.15% year-over-year, with the annual reading at $37.1 million for FY2025, 214.15% up from the prior year.
  • Cash & Equivalents was $37.1 million for Q4 2025 at Gyre Therapeutics, up from $27.2 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $107.0 million in Q1 2021 and troughed at $2.2 million in Q3 2023.
  • The 5-year median for Cash & Equivalents is $24.1 million (2022), against an average of $32.2 million.
  • Year-over-year, Cash & Equivalents plummeted 90.35% in 2023 and then surged 612.12% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $46.9 million in 2021, then tumbled by 46.27% to $25.2 million in 2022, then crashed by 57.97% to $10.6 million in 2023, then increased by 11.51% to $11.8 million in 2024, then soared by 214.15% to $37.1 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Cash & Equivalents are $37.1 million (Q4 2025), $27.2 million (Q3 2025), and $28.6 million (Q2 2025).